Preliminary Findings of Community Liver Health Check Programme: Detection of asymptomatic advanced chronic liver disease

Aims: Chronic liver disease is a leading cause of death worldwide and has a significant social and financial burden on society. Early identification of advanced liver fibrosis/cirrhosis can improve outcomes for patients through both lifestyle and pharmaceutical interventions. NHS England commenced a community screening pilot programme aiming to identify those with advanced fibrosis and cirrhosis using fibroscan with subsequent referral to secondary care for definitive diagnosis of advanced chronic liver disease (ACLD). The goal of the pilot was to identify effective strategies for targeted screening and subsequent referral. We report the preliminary findings of this Community Liver Health Check programme.Methods: Adults with a history of known alcohol-related liver disease; high alcohol use (defined as >30 units/week); known or at risk of hepatitis C or B; known metabolic dysfunction-associated steatotic liver disease (MASLD) or those at risk of MASLD (defined as those aged >50 with BMI >30 or BMI >27 for ethnic minority groups or a diagnosis of type 2 diabetes), were invited for a liver health check by fibroscan in community and non-typical health care settings. Data were collated nationally on numbers of people screened, routes of screening and LSM results. Results: 101,428 fibroscans were undertaken, from which 7,892 (8%) people had aliver stiffness measures >11.5 kPa and were subsequently referred to specialist care. High numbers of people with probable ACLD were identified by offering fibroscans in primary care (10.7%), secondary care (10.8%) and drug and alcohol units (11.2%), whilst non-targeted walk-in public scanning events had the lowest yield(3.4%). Conclusion: Extending non-invasive fibrosis assessment beyond specialist hospital care settings successfully identifies persons at increased risk of ACLD for further assessment in secondary care.. . Patient-level and long-term outcome data is needed to ascertain the benefit of community based screening.

Authors

Publication Details

Journal
Repository@Nottingham (University of Nottingham)
Published
2026-11-12
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Preliminary Findings of Community Liver Health Check Programme: Detection of asymptomatic advanced chronic liver disease

Rohini Sharma, Aloysious Dominic Aravinthan, Vanessa Hebditch, Janisha Patel et al.
Repository@Nottingham (University of Nottingham)
Liver Disease Diagnosis and Treatment
article

Preliminary Findings of Community Liver Health Check Programme: Detection of asymptomatic advanced chronic liver disease

Rohini Sharma, Aloysious Dominic Aravinthan, Vanessa Hebditch, Janisha Patel, Maria Qurashi, Coral Hollywood, Stuart McPherson, Benjamin Stenberg, Mathew Vithayathil, Katharine Caddick, Risha Dattani, Rebecca Jones, Emmanouil Tsochatzis, Tim Cross, Ian Row, Douglas McDonald, Graham Foster, James Franklin
article en

Abstract

Aims: Chronic liver disease is a leading cause of death worldwide and has a significant social and financial burden on society. Early identification of advanced liver fibrosis/cirrhosis can improve outcomes for patients through both lifestyle and pharmaceutical interventions. NHS England commenced a community screening pilot programme aiming to identify those with advanced fibrosis and cirrhosis using fibroscan with subsequent referral to secondary care for definitive diagnosis of advanced chronic liver disease (ACLD). The goal of the pilot was to identify effective strategies for targeted screening and subsequent referral. We report the preliminary findings of this Community Liver Health Check programme.Methods: Adults with a history of known alcohol-related liver disease; high alcohol use (defined as >30 units/week); known or at risk of hepatitis C or B; known metabolic dysfunction-associated steatotic liver disease (MASLD) or those at risk of MASLD (defined as those aged >50 with BMI >30 or BMI >27 for ethnic minority groups or a diagnosis of type 2 diabetes), were invited for a liver health check by fibroscan in community and non-typical health care settings. Data were collated nationally on numbers of people screened, routes of screening and LSM results. Results: 101,428 fibroscans were undertaken, from which 7,892 (8%) people had aliver stiffness measures >11.5 kPa and were subsequently referred to specialist care. High numbers of people with probable ACLD were identified by offering fibroscans in primary care (10.7%), secondary care (10.8%) and drug and alcohol units (11.2%), whilst non-targeted walk-in public scanning events had the lowest yield(3.4%). Conclusion: Extending non-invasive fibrosis assessment beyond specialist hospital care settings successfully identifies persons at increased risk of ACLD for further assessment in secondary care.. . Patient-level and long-term outcome data is needed to ascertain the benefit of community based screening.

Repository@Nottingham (University of Nottingham)
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon